NEW YORK (GenomeWeb) – Invitae and Alnylam Pharmaceuticals have together launched a free genetic testing service called Alnylam Act to encourage early testing and diagnosis for hereditary ATTR amyloidosis.

Through this program, funded by Alnylam, Invitae will perform free testing using one of its comprehensive gene panels for cardiomyopathy, neuropathy, or amyloidosis. Patients eligible for free testing are those in the US who are suspected to have the disease or a family history of it.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.